Hudson Valley Investment Advisors Inc Bristol Myers Squibb CO Transaction History

Hudson Valley Investment Advisors Inc

  • $903 Million
  • Q3 2024

A detailed history of Hudson Valley Investment Advisors Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Hudson Valley Investment Advisors Inc holds 12,510 shares of BMY stock, worth $677,291. This represents 0.07% of its overall portfolio holdings.

Number of Shares
12,510
Previous 15,426 18.9%
Holding current value
$677,291
Previous $640,000 1.09%
% of portfolio
0.07%
Previous 0.08%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024
SELL
$39.66 - $51.75 $115,648 - $150,903
-2,916 Reduced 18.9%
12,510 $647,000
Q2 2024

Jul 02, 2024
BUY
$40.25 - $52.99 $55,987 - $73,709
1,391 Added 9.91%
15,426 $640,000
Q1 2024

Apr 12, 2024
SELL
$47.98 - $54.4 $52,346 - $59,350
-1,091 Reduced 7.21%
14,035 $761,000
Q4 2023

Jan 12, 2024
SELL
$48.48 - $57.85 $107,868 - $128,716
-2,225 Reduced 12.82%
15,126 $776,000
Q3 2023

Oct 27, 2023
SELL
$57.89 - $64.73 $76,183 - $85,184
-1,316 Reduced 7.05%
17,351 $1.01 Million
Q2 2023

Jul 17, 2023
SELL
$63.71 - $70.74 $65,239 - $72,437
-1,024 Reduced 5.2%
18,667 $1.19 Million
Q1 2023

Apr 06, 2023
SELL
$65.71 - $74.53 $20,698 - $23,476
-315 Reduced 1.57%
19,691 $1.36 Million
Q4 2022

Jan 31, 2023
SELL
$68.48 - $81.09 $39,718 - $47,032
-580 Reduced 2.82%
20,006 $1.44 Million
Q3 2022

Oct 11, 2022
SELL
$0.13 - $76.84 $108 - $64,315
-837 Reduced 3.91%
20,586 $1.46 Million
Q2 2022

Jul 18, 2022
SELL
$72.62 - $79.98 $60,274 - $66,383
-830 Reduced 3.73%
21,423 $1.65 Million
Q1 2022

Apr 20, 2022
SELL
$61.48 - $73.72 $37,810 - $45,337
-615 Reduced 2.69%
22,253 $1.63 Million
Q4 2021

Jan 24, 2022
SELL
$53.63 - $62.52 $5,363 - $6,252
-100 Reduced 0.44%
22,868 $1.43 Million
Q3 2021

Oct 26, 2021
SELL
$59.17 - $69.31 $46,448 - $54,408
-785 Reduced 3.3%
22,968 $1.36 Million
Q2 2021

Jul 07, 2021
SELL
$61.91 - $67.42 $71,196 - $77,533
-1,150 Reduced 4.62%
23,753 $1.59 Million
Q1 2021

Apr 23, 2021
SELL
$59.34 - $66.74 $65,274 - $73,414
-1,100 Reduced 4.23%
24,903 $1.57 Million
Q4 2020

Jan 15, 2021
SELL
$57.74 - $65.43 $17,322 - $19,629
-300 Reduced 1.14%
26,003 $1.61 Million
Q3 2020

Oct 13, 2020
SELL
$57.43 - $63.64 $51,112 - $56,639
-890 Reduced 3.27%
26,303 $1.59 Million
Q2 2020

Jul 07, 2020
SELL
$54.82 - $64.09 $20,612 - $24,097
-376 Reduced 1.36%
27,193 $1.6 Million
Q1 2020

Apr 29, 2020
SELL
$46.4 - $67.43 $20,230 - $29,399
-436 Reduced 1.56%
27,569 $1.54 Million
Q4 2019

Jan 17, 2020
BUY
$49.21 - $64.19 $311,007 - $405,680
6,320 Added 29.14%
28,005 $1.8 Million
Q3 2019

Oct 18, 2019
BUY
$42.77 - $50.71 $213 - $253
5 Added 0.02%
21,685 $1.1 Million
Q2 2019

Jul 16, 2019
SELL
$44.62 - $49.34 $17,624 - $19,489
-395 Reduced 1.79%
21,680 $983,000
Q1 2019

Apr 10, 2019
SELL
$45.12 - $53.8 $251,814 - $300,257
-5,581 Reduced 20.18%
22,075 $1.05 Million
Q4 2018

Jan 17, 2019
BUY
$48.76 - $63.23 $77,967 - $101,104
1,599 Added 6.14%
27,656 $1.44 Million
Q3 2018

Oct 12, 2018
SELL
$55.19 - $62.25 $20,475 - $23,094
-371 Reduced 1.4%
26,057 $1.62 Million
Q2 2018

Jul 10, 2018
SELL
$50.53 - $62.98 $9,903 - $12,344
-196 Reduced 0.74%
26,428 $1.46 Million
Q1 2018

Apr 12, 2018
SELL
$59.92 - $68.98 $109,174 - $125,681
-1,822 Reduced 6.41%
26,624 $1.68 Million
Q4 2017

Jan 16, 2018
SELL
$59.94 - $65.35 $22,297 - $24,310
-372 Reduced 1.29%
28,446 $1.74 Million
Q3 2017

Oct 13, 2017
BUY
$55.23 - $63.74 $1.59 Million - $1.84 Million
28,818
28,818 $1.84 Million

Others Institutions Holding BMY

# of Institutions
2,468
Shares Held
1.5B
Call Options Held
29.6M
Put Options Held
32.2M
View Full List

About BRISTOL MYERS SQUIBB CO

BMY Quotes by TradingView
  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $115B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Hudson Valley Investment Advisors Inc Portfolio

Follow Hudson Valley Investment Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Valley Investment Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Hudson Valley Investment Advisors Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email